We need a "made in Canada" orphan drug framework

CMAJ

Volumn 189, Issue 41, 2017, Pages E1274-E1275

  McMillan, Hugh J ^a   Campbell, Craig ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; GENERIC DRUG; NUSINERSEN; ORPHAN DRUG;

BUDGET; CANADA; CHILDHOOD DISEASE; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DUCHENNE MUSCULAR DYSTROPHY; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; NOTE; PATENT; RARE DISEASE; REIMBURSEMENT; RESOURCE ALLOCATION; SPINAL MUSCULAR ATROPHY; TEACHING HOSPITAL; DRUG MANUFACTURE; ECONOMICS; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; RARE DISEASES;

CANADA; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 85032498017     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.170195     Document Type: Note

References (11)

1. Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One 2015;10:e0140002.
2. Office of Legislative and Regulatory Modernization. Initial draft discussion document for a Canadian orphan drug regulatory framework. 2012. Available: www.orpha.net/national/data/CA-EN/www/uploads/Initial-Draft-Discussion-Document-for-A-Canadian-Orphan-Drug-Regulatory-Framework.doc (accessed 2017 July 7).
3. Herder M. When everyone is an orphan: against adopting a US styled orphan drug policy in Canada. Account Res 2013;20:227-69.
4. Morgan SG, Bassett KL, Wright JM, et al. "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ 2005:331:815-6.
5. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016;388:3017-26.
6. Thomas K. Costly drug for fatal muscular disease wins FDA approval. The New York Times 2016 Dec. 30. Available: www.nytimes.com/2016/12/30/business/spinraza-price.html (accessed 2017 July 7).
7. Walker J. PTC expects net price of $35, 000 annually per patient for Emflaza. The Wall Street Journal 2017 May 8. Available: www.wsj.com/articles/ptc-expects-net-price-of-35-000-annually-per-patient-for-emflaza-1494254575 (accessed 2017 July 7).
8. Côté A, Keating B. What is wrong with orphan drug policies? Value Health 2012;15:1185-91.
9. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity. Health Policy 2010;95:216-28.
10. Valverde AM, Reed SD, Schulman KA. Proposed "grant-and-access" program with price caps could stimulate development of drugs for very rare diseases. Health Aff (Millwood) 2012;31:2528-35.
11. Lee DK, Wong B. An orphan drug framework (ODF) for Canada. J Popul Ther Clin Pharmacol 2014;21:e42-6.